Published in Mol Cell on June 01, 2003
Targeting the mTOR signaling network for cancer therapy. J Clin Oncol (2009) 4.52
Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther (2009) 1.98
Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat (2008) 1.90
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene (2008) 1.64
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
Microarrays of small molecules embedded in biodegradable polymers for use in mammalian cell-based screens. Proc Natl Acad Sci U S A (2004) 1.48
Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol (2011) 1.46
Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.43
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol (2004) 1.39
TOR signaling is a determinant of cell survival in response to DNA damage. Mol Cell Biol (2007) 1.28
DDB2 decides cell fate following DNA damage. Proc Natl Acad Sci U S A (2009) 1.22
Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer (2006) 1.17
The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol (2009) 1.11
Negative regulation of ASK1 by p21Cip1 involves a small domain that includes Serine 98 that is phosphorylated by ASK1 in vivo. Mol Cell Biol (2007) 1.09
Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-x(L) inhibition. PLoS One (2011) 1.07
Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons. J Vasc Surg (2007) 1.07
Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis (2012) 1.03
Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One (2010) 1.02
JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest (2009) 1.01
BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways. J Cell Biol (2008) 1.00
Inhibition of SAPK2/p38 enhances sensitivity to mTORC1 inhibition by blocking IRES-mediated translation initiation in glioblastoma. Mol Cancer Ther (2011) 0.99
Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim Biophys Acta (2008) 0.99
4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1. Cell Cycle (2012) 0.98
E2F1 death pathways as targets for cancer therapy. J Cell Mol Med (2007) 0.97
The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica (2010) 0.97
Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in alpha4- and protein phosphatase 2A-dependent fashion. J Biol Chem (2009) 0.96
Effects of 4E-BP1 expression on hypoxic cell cycle inhibition and tumor cell proliferation and survival. Cancer Biol Ther (2008) 0.95
DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response. Cell Cycle (2009) 0.94
AP-1 regulates cyclin D1 and c-MYC transcription in an AKT-dependent manner in response to mTOR inhibition: role of AIP4/Itch-mediated JUNB degradation. Mol Cancer Res (2010) 0.92
Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget (2015) 0.91
Therapeutic potential and adverse events of everolimus for treatment of hepatocellular carcinoma - systematic review and meta-analysis. Cancer Med (2013) 0.91
Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A. Neuropharmacology (2016) 0.89
At the crossroads of polarity, proliferation and apoptosis: the use of Drosophila to unravel the multifaceted role of endocytosis in tumor suppression. Mol Oncol (2009) 0.87
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood (2016) 0.87
Celastrol prevents cadmium-induced neuronal cell death via targeting JNK and PTEN-Akt/mTOR network. J Neurochem (2013) 0.87
Novel role of c-jun N-terminal kinase in regulating the initiation of cap-dependent translation. Int J Oncol (2011) 0.85
Vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun-dependent signaling. J Virol (2006) 0.84
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia (2012) 0.83
mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death. PLoS One (2014) 0.83
Protein kinase C delta (PKCδ) affects proliferation of insulin-secreting cells by promoting nuclear extrusion of the cell cycle inhibitor p21Cip1/WAF1. PLoS One (2011) 0.82
Benzo(a)pyrene-caused increased G1-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts. Toxicol Lett (2008) 0.81
Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo. PLoS One (2012) 0.81
Androgen via p21 inhibits tumor necrosis factor alpha-induced JNK activation and apoptosis. J Biol Chem (2009) 0.80
Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways. Neuropharmacology (2015) 0.77
Targeting angiogenesis in childhood sarcomas. Sarcoma (2010) 0.77
Inhibition of JNK-mediated autophagy enhances NSCLC cell sensitivity to mTORC1/2 inhibitors. Sci Rep (2016) 0.76
Model Predicts That MKP1 and TAB1 Regulate p38α Nuclear Pulse and Its Basal Activity through Positive and Negative Feedback Loops in Response to IL-1. PLoS One (2016) 0.76
Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy. Autophagy (2016) 0.75
The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma. BMC Cancer (2015) 0.75
Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair. Oncotarget (2016) 0.75
TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget (2016) 0.75
Effect of SP600125 on the mitotic spindle in HeLa Cells, leading to mitotic arrest, endoreduplication and apoptosis. Mol Cytogenet (2016) 0.75
An insight of rapamycin against cadmium's neurotoxicity. Oncotarget (2017) 0.75
Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells. Oncotarget (2016) 0.75
Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep (2017) 0.75
Integrin-linked kinase: both Jekyll and Hyde in rhabdomyosarcoma. J Clin Invest (2009) 0.75
Serine/Threonine Protein Phosphatase-5 Accelerates Cell Growth and Migration in Human Glioma. Cell Mol Neurobiol (2015) 0.75
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev (2002) 6.44
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat Methods (2011) 5.34
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol (2005) 4.32
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med (2004) 2.82
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (2007) 2.71
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
Activation of apoptosis signal-regulating kinase 1 by the stress-induced activating phosphorylation of pre-formed oligomer. J Cell Physiol (2002) 2.69
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
ALS-linked mutant SOD1 induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. Genes Dev (2008) 2.43
Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta (2008) 2.31
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. Proc Natl Acad Sci U S A (2005) 1.91
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol (2008) 1.85
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem (2002) 1.79
The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res (2009) 1.79
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest (2004) 1.79
Recruitment of tumor necrosis factor receptor-associated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem (2005) 1.78
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. Nat Genet (2013) 1.77
Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A (2003) 1.73
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
The ASK1-MAP kinase cascades in mammalian stress response. J Biochem (2004) 1.70
Thioredoxin and TRAF family proteins regulate reactive oxygen species-dependent activation of ASK1 through reciprocal modulation of the N-terminal homophilic interaction of ASK1. Mol Cell Biol (2007) 1.68
Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.66
Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol Chem (2003) 1.64
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res (2003) 1.63
Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem (2002) 1.61
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol (2007) 1.61
Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal (2002) 1.59
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res (2003) 1.58
Roles of MAPKKK ASK1 in stress-induced cell death. Cell Struct Funct (2003) 1.58
A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis-linked SOD1 mutants. Ann Neurol (2012) 1.55
Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs (2002) 1.52
Retracted FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol (2005) 1.51
Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav (2003) 1.48
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res (2004) 1.47
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer (2010) 1.47
ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. EMBO J (2009) 1.46
Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal (2005) 1.45
Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth. Mol Cell Biol (2006) 1.45
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Involvement of ASK1 in Ca2+-induced p38 MAP kinase activation. EMBO Rep (2004) 1.42
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res (2004) 1.41
Identification of N10-substituted phenoxazines as potent and specific inhibitors of Akt signaling. J Biol Chem (2005) 1.41
The loss of PGAM5 suppresses the mitochondrial degeneration caused by inactivation of PINK1 in Drosophila. PLoS Genet (2010) 1.41
Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J Neurooncol (2006) 1.38
4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem (2002) 1.37
Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity. J Biol Chem (2004) 1.37
Requirement of reactive oxygen species-dependent activation of ASK1-p38 MAPK pathway for extracellular ATP-induced apoptosis in macrophage. J Biol Chem (2008) 1.36
Pathophysiological roles of ASK1-MAP kinase signaling pathways. J Biochem Mol Biol (2007) 1.34
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther (2006) 1.32
Antioxidant activity of methanol extracts obtained from Plantago species. J Agric Food Chem (2005) 1.32
The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal (2009) 1.32
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
Reaper-mediated inhibition of DIAP1-induced DTRAF1 degradation results in activation of JNK in Drosophila. Nat Cell Biol (2002) 1.31
Apoptosis signal-regulating kinase (ASK) 2 functions as a mitogen-activated protein kinase kinase kinase in a heteromeric complex with ASK1. J Biol Chem (2007) 1.31
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Stat Med (2003) 1.30
The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med (2006) 1.30
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms. Mol Pharmacol (2009) 1.29
ASK1-p38 MAPK-p47phox activation is essential for inflammatory responses during tuberculosis via TLR2-ROS signalling. Cell Microbiol (2007) 1.29
Survival and apoptosis signals in ER stress: the role of protein kinases. J Chem Neuroanat (2004) 1.29
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
Thioredoxin and protein kinases in redox signaling. Semin Cancer Biol (2006) 1.27
In vitro cytotoxic activity of Thai medicinal plants used traditionally to treat cancer. J Ethnopharmacol (2004) 1.27
Small-sample inference for incomplete longitudinal data with truncation and censoring in tumor xenograft models. Biometrics (2002) 1.26
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.26
Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug. Cancer Res (2003) 1.26
Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell (2003) 1.26
Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res (2003) 1.26